South Korea's Exports Hit Record High in March on AI-Driven Chip Demand 
Goldman Sachs Sees Value in European Real Estate Stocks Despite Sharp Selloff 
Asian Stocks Mixed in March 2026 Amid Iran War Fears and Tech Selloff 
WTO Ministerial Collapse Leaves Global Digital Trade Rules in Limbo 
Asian Stocks Surge on Trump's Iran War Comments and Dip-Buying 
U.S. Stocks Surge on Iran War De-escalation Hopes 
Iran Strikes Oil Tanker Near Dubai Amid U.S. Threats and Ongoing Middle East Conflict 
Bessent: Global Oil Market Well Supplied as U.S. Eyes Hormuz Navigation Control 
Gold Prices Rebound in Asia Amid Iran War Ceasefire Hopes 
U.S. Trade Rep Dismisses WTO's Future Role After Failed Cameroon Summit 
Oil Prices Climb as Middle East Conflict Keeps Supply Risks Elevated 
Japan's Business Confidence Rises Despite Iran War Uncertainty, BOJ Rate Hike Expected 
U.S. Stock Futures Surge After WSJ Report on Trump's Iran War Exit Strategy 
Australia Bans Card Payment Surcharges Starting October 2025 
Aluminum Prices Surge Toward Four-Year Highs After Gulf Smelter Strikes 
South Korea Manufacturing PMI Hits 4-Year High in March 2025 Driven by Semiconductor Demand 
Japan Business Sentiment Rises as Iran War Fuels Inflation Fears, BOJ Rate Hike Looms 
Eli Lilly to Introduce Mounjaro Weight-Loss Drug in Hong Kong by Year-End
Global pharmaceutical giant Eli Lilly is gearing up to launch its weight-loss drug, Mounjaro, in Hong Kong by the end of this year. According to a report from Bloomberg News, the company has received approval from Hong Kong's government to sell its tirzepatide injections under the Mounjaro brand.
Mounjaro for Weight Management and Diabetes
Eli Lilly's Mounjaro is designed for both long-term weight management and the treatment of type 2 diabetes. It will be available on the Kwikpen device, which allows for easy self-administration. The company aims to address the growing demand for effective weight-loss treatments while continuing to provide solutions for diabetes management.
Hong Kong Market Entry
Hong Kong marks a strategic entry point for Eli Lilly as it expands its global presence. With the approval of Mounjaro, the company is poised to offer a highly anticipated solution for individuals struggling with obesity and related health issues. The weight-loss sector has seen significant growth in recent years, and Mounjaro is expected to make a notable impact.
